140 related articles for article (PubMed ID: 22125107)
1. [Chromogranin A (CgA) - the influence of various factors in vivo and in vitro, and existing disorders on it's concentration in blood].
Glinicki P; Jeske W
Endokrynol Pol; 2011; 62 Suppl 1():25-8. PubMed ID: 22125107
[TBL] [Abstract][Full Text] [Related]
2. Chromogranin A (CgA)--the influence of various factors in vivo and in vitro, and existing disorders on it's concentration in blood.
Glinicki P; Jeske W
Endokrynol Pol; 2010; 61(4):384-7. PubMed ID: 20806183
[TBL] [Abstract][Full Text] [Related]
3. [Chromogranin A (CgA) - characteristic of the currently available laboratory methods and conditions which can influence the results].
Glinicki P; Jeske W
Endokrynol Pol; 2009; 60(5):415-9. PubMed ID: 19885814
[TBL] [Abstract][Full Text] [Related]
4. [Current diagnostic procedure on neuroendocrine differentiation of prostate cancer].
Sciarra A; Innocenzi M; Ravaziol M; Minisola F; Alfarone A; Cattarino S; Panebianco V; Buonocore V; Gentile V; Di Silverio F
Urologia; 2011; 78(2):132-6. PubMed ID: 21574146
[TBL] [Abstract][Full Text] [Related]
5. The differences in chromogranin A (CgA) concentrations measured in serum and in plasma by IRMA and ELISA methods.
Glinicki P; Kapuścińska R; Jeske W
Endokrynol Pol; 2010; 61(4):346-50. PubMed ID: 20806177
[TBL] [Abstract][Full Text] [Related]
6. Comparison of chromogranin A (CgA) levels in serum and plasma (EDTA2K) and the respective reference ranges in healthy males.
Glinicki P; Jeske W; Kapuścińska R; Zgliczyński W
Endokrynol Pol; 2015; 66(1):53-6. PubMed ID: 25754282
[TBL] [Abstract][Full Text] [Related]
7. Routine measurement of plasma chromogranin B has limited clinical utility in the management of patients with neuroendocrine tumours.
Monaghan PJ; Lamarca A; Valle JW; Hubner RA; Mansoor W; Trainer PJ; Darby D
Clin Endocrinol (Oxf); 2016 Mar; 84(3):348-52. PubMed ID: 26608723
[TBL] [Abstract][Full Text] [Related]
8. Circulating chromogranin A and its fragments as diagnostic and prognostic disease markers.
Corti A; Marcucci F; Bachetti T
Pflugers Arch; 2018 Jan; 470(1):199-210. PubMed ID: 29018988
[TBL] [Abstract][Full Text] [Related]
9. Hypergastrinemia as a cause of chromogranin a increase in blood in patients suspected to have neuroendocrine tumor.
Kleveland O; Syversen U; Slørdahl K; Waldum HL
Digestion; 2001; 64(2):71-4. PubMed ID: 11684818
[TBL] [Abstract][Full Text] [Related]
10. Significance of plasma chromogranin A determination in neuroendocrine tumour (NET) diagnosis.
Donica H; Malecha-Jędraszek A; Strosławska E; Burska A; Szubstarski F
Folia Histochem Cytobiol; 2010 Dec; 48(4):603-10. PubMed ID: 21478104
[TBL] [Abstract][Full Text] [Related]
11. Chromogranin A: any relevance in neuroendocrine tumors?
Kidd M; Bodei L; Modlin IM
Curr Opin Endocrinol Diabetes Obes; 2016 Feb; 23(1):28-37. PubMed ID: 26627724
[TBL] [Abstract][Full Text] [Related]
12. Octreotide suppression test in diagnosing and predicting the outcome of therapy in patients with neuroendocrine tumors. Preliminary report.
Kos-Kudła B; Zemczak A; Foltyn W; Marek B; Strzelczyk J; Telega A; Zajecki W; Legaszewski T; Jurecka-Lubieniecka B
Endokrynol Pol; 2007; 58(2):123-9. PubMed ID: 17578828
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine tumours of the small bowel: interpretation of raised circulating chromogranin A, urinary 5 hydroxy indole acetic acid and circulating neurokinin A.
Ardill JE; Armstrong L; Smye M; Doherty R; McCance DR; Johnston BT
QJM; 2016 Feb; 109(2):111-5. PubMed ID: 25979268
[TBL] [Abstract][Full Text] [Related]
14. The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases.
Han X; Zhang C; Tang M; Xu X; Liu L; Ji Y; Pan B; Lou W
Eur J Gastroenterol Hepatol; 2015 May; 27(5):527-35. PubMed ID: 25822862
[TBL] [Abstract][Full Text] [Related]
15. Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame.
Marotta V; Zatelli MC; Sciammarella C; Ambrosio MR; Bondanelli M; Colao A; Faggiano A
Endocr Relat Cancer; 2018 Jan; 25(1):R11-R29. PubMed ID: 29066503
[TBL] [Abstract][Full Text] [Related]
16. Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors.
Hijioka M; Ito T; Igarashi H; Fujimori N; Lee L; Nakamura T; Jensen RT; Takayanagi R
Cancer Sci; 2014 Nov; 105(11):1464-71. PubMed ID: 25220535
[TBL] [Abstract][Full Text] [Related]
17. Chromogranin A predicts survival for resected pancreatic neuroendocrine tumors.
Shanahan MA; Salem A; Fisher A; Cho CS; Leverson G; Winslow ER; Weber SM
J Surg Res; 2016 Mar; 201(1):38-43. PubMed ID: 26850182
[TBL] [Abstract][Full Text] [Related]
18. Measurements of chromogranin B can serve as a complement to chromogranin A.
Stridsberg M; Eriksson B; Fellström B; Kristiansson G; Tiensuu Janson E
Regul Pept; 2007 Mar; 139(1-3):80-3. PubMed ID: 17116339
[TBL] [Abstract][Full Text] [Related]
19. Automated two-site immunofluorescent assay for the measurement of serum chromogranin A.
Popovici T; Moreira B; Schlageter MH; Bories PN
Clin Biochem; 2014 Jan; 47(1-2):87-91. PubMed ID: 24201067
[TBL] [Abstract][Full Text] [Related]
20. Prospective Study of Chromogranin A as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine Tumors.
Dam G; Grønbæk H; Sorbye H; Thiis Evensen E; Paulsson B; Sundin A; Jensen C; Ebbesen D; Knigge U; Tiensuu Janson E
Neuroendocrinology; 2020; 110(3-4):217-224. PubMed ID: 31578011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]